| Treatment of primary Sjögren syndrome with rituximab: a randomized trial V Devauchelle-Pensec, X Mariette, S Jousse-Joulin, JM Berthelot, ... Annals of internal medicine 160 (4), 233-242, 2014 | 467 | 2014 |
| Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial JE Gottenberg, P Ravaud, X Puéchal, V Le Guern, J Sibilia, V Goeb, ... Jama 312 (3), 249-258, 2014 | 359 | 2014 |
| Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient … R Seror, H Bootsma, A Saraux, SJ Bowman, E Theander, JG Brun, ... Annals of the rheumatic diseases 75 (2), 382-389, 2016 | 316 | 2016 |
| Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss AP Trouvin, V Goëb Clinical interventions in aging, 345-354, 2010 | 308 | 2010 |
| Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? B Saleem, H Keen, V Goeb, R Parmar, S Nizam, EMA Hensor, ... Annals of the rheumatic diseases 69 (9), 1636-1642, 2010 | 244 | 2010 |
| Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren’s syndrome. Data at enrollment in … JE Gottenberg, R Seror, C Miceli-Richard, J Benessiano, ... PloS one 8 (5), e59868, 2013 | 217 | 2013 |
| Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data … P Brito-Zerón, N Acar-Denizli, M Zeher, A Rasmussen, R Seror, ... Annals of the rheumatic diseases 76 (6), 1042-1050, 2017 | 185 | 2017 |
| Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re‐treatment EM Vital, S Dass, AC Rawstron, MH Buch, V Goeb, K Henshaw, ... Arthritis & Rheumatism 62 (5), 1273-1279, 2010 | 168 | 2010 |
| Severe Health‐Related quality of life impairment in active primary Sjögren's syndrome and Patient‐Reported outcomes: data from a large therapeutic trial D Cornec, V Devauchelle‐Pensec, X Mariette, S Jousse‐Joulin, ... Arthritis Care & Research 69 (4), 528-535, 2017 | 155* | 2017 |
| Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature JM Berthelot, M De Bandt, P Goupille, E Solau-Gervais, F Lioté, V Goeb, ... Joint Bone Spine 76 (1), 28-34, 2009 | 148 | 2009 |
| Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes V Goëb, M Thomas-L'Otellier, R Daveau, R Charlionet, P Fardellone, ... Arthritis research & therapy 11, 1-14, 2009 | 136 | 2009 |
| Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease. A nationwide series É Toussirot, É Houvenagel, V Goëb, D Fouache, A Martin, P Le Dantec, ... Joint Bone Spine 79 (5), 457-463, 2012 | 131 | 2012 |
| Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study D Fouache, V Goeb, N Massy-Guillemant, G Avenel, ... Rheumatology 48 (7), 761-764, 2009 | 121 | 2009 |
| European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient‐Reported Index: A Complete … R Seror, JE Gottenberg, V Devauchelle‐Pensec, JJ Dubost, V Le Guern, ... Arthritis care & research 65 (8), 1358-1364, 2013 | 114 | 2013 |
| Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised … JR Tarn, N Howard-Tripp, DW Lendrem, X Mariette, A Saraux, ... The Lancet Rheumatology 1 (2), e85-e94, 2019 | 108 | 2019 |
| Bone remodelling markers in rheumatoid arthritis P Fardellone, A Séjourné, J Paccou, V Goëb Mediators of inflammation 2014, 2014 | 106 | 2014 |
| Characteristics and outcomes of COVID‐19 in hospitalized patients with and without diabetes A Al‐Salameh, JP Lanoix, Y Bennis, C Andrejak, E Brochot, G Deschasse, ... Diabetes/metabolism research and reviews 37 (3), e3388, 2021 | 104 | 2021 |
| Anti-annexin II antibodies in systemic autoimmune diseases and antiphospholipid syndrome V Salle, JC Maziere, A Smail, R Cévallos, C Mazière, V Fuentes, ... Journal of clinical immunology 28, 291-297, 2008 | 95 | 2008 |
| Clinical significance of autoantibodies recognizing Sjögren's syndrome A (SSA), SSB, calpastatin and alpha-fodrin in primary Sjögren's syndrome V Goëb, V Salle, P Duhaut, F Jouen, A Smail, JP Ducroix, F Tron, ... Clinical & Experimental Immunology 148 (2), 281-287, 2007 | 86 | 2007 |
| Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. T Lequerré, O Vittecoq, N Klemmer, V Goëb, S Pouplin, JF Menard, ... The Journal of Rheumatology 33 (7), 1307-1314, 2006 | 86 | 2006 |
Alain SarauxU1227Verified email at chu-brest.fr
